Vaginal Progesterone Equally Effective in Achieving Pregnancy Outcomes as Injectable in DE Cycles

Photo by bies
Vaginal Progesterone is Equally Effective in Achieving Pregnancy Outcomes as Injectable Progesterone in Donor Egg Cycles

A retrospective analysis conducted at a large infertility center evaluated pregnancy outcomes for 225 donor egg recipients

A retrospective analysis of anonymous oocyte (egg) donation cycles, comparing the pregnancy outcomes between vaginally-administered progesterone versus intramuscular (IM) progesterone injections, demonstrates that vaginally-administered progesterone and IM progesterone achieve equal pregnancy outcomes, according to data presented by Brian Berger, MD, Boston IVF, at the Pacific Coast Reproductive Society annual meeting in Rancho Mirage, CA. The retrospective study was supported by a grant from Columbia Laboratories, Inc. (NASDAQ:CBRX).

“We found no significant differences in pregnancy outcomes between patients treated with vaginal progesterone versus progesterone administered intramuscularly,” said Dr. Berger. “Further, vaginal progesterone has the added advantage of avoiding painful intramuscular injections.”

In 225 egg donor cycles, 105 patients received vaginally-administered progesterone (CRINONE® 8% (a bioadhesive progesterone gel)) and 120 received IM progesterone. The implantation rate was 43.8% for vaginal progesterone versus 37.1% for IM progesterone (p=0.175). Recipients treated with vaginal progesterone achieved a 58.1% pregnancy rate and a 51.4% delivery rate, versus a 53.3% pregnancy rate (p=0.503) and a 48.3% delivery rate (p=0.689) for patients receiving IM progesterone. The pregnancy loss rate was 10.5% for patients using vaginal progesterone and 10.8% for IM progesterone users (p=1.00).

“This study clearly demonstrates that vaginal progesterone gel achieves the same pregnancy outcomes as progesterone administered via an intramuscular injection. This is important confirmation that CRINONE® 8% offers patients an efficacious and more convenient option for providing progesterone support in infertility treatment,” Berger added.

Boston IVF is one of America’s most successful fertility centers, providing patients with unparalleled medical care and the best experience with the expertise of premier doctors and professional staff, who are affiliated with Harvard Medical School. It is world renowned for its highly successful and innovative infertility treatments, highest quality service, state-of-the-art methods, ongoing scientific research, and on-site complementary healthcare at its Domar Center.

About Progesterone and Luteal Phase Support

Progesterone is the pregnancy hormone that creates a healthy environment in a woman’s uterus where a fertilized egg can implant and grow into a healthy baby. Most women undergoing infertility treatment need additional progesterone to help prepare the uterus for implantation and development of a fertilized egg.

Before ovulation, progesterone levels in a woman’s body remain relatively low, but rise after ovulation during the latter part of a woman’s menstrual cycle which is called the luteal phase. The luteal phase begins with the production of progesterone and ends with either pregnancy or menstruation, when the uterus sheds its lining. During pregnancy, progesterone helps to maintain the lining of the uterus, providing necessary nutrients to support and nurture a fertilized egg.

Source: http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20080414005254&newsLang=en

Category: Donor Egg, implantation, ovulation, progesterone